Point-of-Care Testing in the Emergency Department

Point-of-care testing (POCT) encompasses diagnostic assays performed at or near the patient's bedside rather than in a central laboratory, enabling clinicians to obtain actionable results within minutes rather than hours. In the emergency department, where diagnostic speed directly affects triage decisions, treatment initiation, and patient throughput, POCT has become a structural component of care delivery. This page covers the definition and regulatory scope of POCT, the technical mechanisms behind common platforms, the clinical scenarios in which POCT is most applied, and the decision boundaries that govern when bedside testing is preferred over central laboratory analysis.

Definition and scope

Point-of-care testing is formally defined by the Centers for Medicare & Medicaid Services (CMS) under the Clinical Laboratory Improvement Amendments (CLIA) framework (42 CFR Part 493) as laboratory testing performed outside a traditional laboratory setting using portable or handheld instrumentation. CLIA categorizes all diagnostic tests into three complexity levels — waived, moderate complexity, and high complexity — and this classification directly determines which personnel may perform the test and what quality controls are mandated.

Most bedside POCT devices used in emergency departments fall into the waived or moderate complexity categories. Waived tests, such as urine dipstick analysis and fingerstick glucose measurement, require minimal training and carry lower regulatory burden. Moderate-complexity assays — including whole-blood electrolyte panels and certain immunoassay-based troponin tests — require documented operator competency and participation in proficiency testing programs administered through CMS-approved bodies such as the College of American Pathologists (CAP).

The regulatory context for emergency medicine is broader than CLIA alone: the Joint Commission's laboratory standards (EC.02.05.01 and related elements) govern how hospitals integrate POCT into quality management systems, and the Food and Drug Administration (FDA) oversees the clearance or approval of the devices themselves under 21 CFR Part 820 (Quality System Regulation).

How it works

POCT platforms in the emergency department operate through several distinct analytical technologies, each suited to different test categories:

Immunoassay lateral flow — Antibody-antigen binding produces a visible line on a nitrocellulose strip. Used for influenza A/B, RSV, SARS-CoV-2, urine hCG, and fecal occult blood. Turnaround time: 10–15 minutes.
Electrochemical biosensors — Enzyme-coated electrodes measure electrical current generated by substrate oxidation. Primary platform for fingerstick glucose (glucose oxidase) and blood gas/electrolyte cartridges. Turnaround time: 2–5 minutes.
Microfluidic cartridge systems — Small volumes of whole blood or plasma are driven through microfabricated channels where optical or electrochemical detection occurs. Used for high-sensitivity troponin I/T, B-type natriuretic peptide (BNP), and prothrombin time/INR. Turnaround time: 8–20 minutes.
Molecular amplification (rapid PCR/LAMP) — Nucleic acid amplification detects pathogen DNA or RNA directly from nasopharyngeal swabs or other specimens. Platforms such as the Cepheid GeneXpert and Abbott ID NOW fall into this category. Turnaround time: 5–45 minutes depending on platform and analyte.
Point-of-care ultrasound (POCUS) — While not a laboratory test, POCUS is frequently classified within the POCT framework as a bedside imaging adjunct; it is addressed separately at Point-of-Care Ultrasound in Emergency Medicine.

Quality control requirements under CLIA mandate that emergency departments running moderate-complexity assays perform two-level liquid quality control at least every 24 hours of testing or as specified by the manufacturer's instructions for use.

Common scenarios

POCT is integrated into emergency department workflows across a range of high-acuity and time-sensitive presentations:

Chest pain evaluation: Whole-blood high-sensitivity troponin assays enable accelerated 0-hour/1-hour or 0-hour/2-hour rule-out protocols for acute myocardial infarction. The European Society of Cardiology (ESC) 2020 guidelines formalized these rapid pathways, and POCT troponin platforms validated against central laboratory reference methods have been incorporated into those algorithms where analytical performance is equivalent.
Sepsis and lactate monitoring: Bedside whole-blood lactate measurement guides fluid resuscitation decisions in suspected sepsis. The Surviving Sepsis Campaign guidelines (2021 update, published in Intensive Care Medicine and Critical Care Medicine) identify lactate ≥ 2 mmol/L as a threshold triggering enhanced monitoring and recommend repeat measurement within 2 hours.
Coagulation status in trauma and anticoagulated patients: Point-of-care INR and activated clotting time (ACT) testing support rapid reversal decisions in hemorrhaging patients or those on warfarin presenting to trauma care in the emergency department.
Respiratory illness differentiation: Multiplex POCT panels simultaneously detect influenza A, influenza B, RSV, and SARS-CoV-2 from a single nasopharyngeal swab, informing isolation precautions and antiviral prescribing within a single patient encounter.
Pregnancy-related emergencies: Bedside urine or serum hCG testing is standard in the evaluation of obstetric and gynecologic emergencies where ectopic pregnancy must be excluded rapidly.
Diabetic emergencies: Glucose and beta-hydroxybutyrate POCT supports the diagnosis and monitoring of diabetic ketoacidosis without awaiting central laboratory metabolic panels.

Decision boundaries

Not all clinical questions are best answered at the bedside. The decision to use POCT versus central laboratory testing involves four structured considerations:

1. Analytical precision requirements
High-sensitivity troponin assays at the 99th percentile reference limit require coefficient of variation (CV) ≤ 10% per the International Federation of Clinical Chemistry (IFCC) working group standards. If a POCT platform cannot meet this threshold, the central laboratory assay is preferred for rule-in/rule-out pathways.

2. Test turnaround time vs. clinical urgency
When central laboratory turnaround time exceeds the clinical decision window — for instance, in a patient with suspected hyperkalemia and widened QRS on ECG — bedside electrolyte measurement is operationally superior regardless of the marginal precision advantage of the central analyzer.

3. Specimen volume and patient population constraints
Neonates and pediatric patients in the emergency department present with venous access challenges; many POCT cartridge systems require as little as 65–100 µL of whole blood, reducing phlebotomy burden compared to standard tube-based collection volumes of 2–4 mL.

4. Regulatory and staffing constraints
Under CLIA, moderate-complexity testing requires that operators demonstrate documented competency assessed on at least 6 performance elements including test performance, quality control, and result reporting. Emergency departments using nursing staff or patient care technicians to perform POCT must maintain competency records subject to CMS inspection. Failure to comply can result in CLIA certificate suspension or revocation affecting the entire facility.

The emergency department operations and flow context matters here: POCT reduces median laboratory turnaround time, but its impact on overall length of stay depends on integration with order-entry workflows, result notification systems, and physician response time — factors that vary by facility infrastructure rather than test platform alone.

The broader landscape of emergency medicine diagnostics, including how POCT fits within the specialty's evidence-based framework, is mapped at the Emergency Medicine Authority index.

References

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)